Web Analytics

Start up Profile

CellCentric

CellCentric United Kingdom - Cambridge
START UP

1 Disclosed Funding Rounds $25,000,000
0 Participating Investments




Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases

Capital Raised

Date Round Raised Participating Investors
July, 24 ,2023 Unknown $25,000,000